Navigation Links
Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/2/2011

MOUNTAIN VIEW, Calif., Nov. 2, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the company will participate in the Lazard Capital Markets 8th Annual Healthcare Conference, being held in New York, New York, November 15 - 16, 2011.  The Alexza corporate presentation will be Tuesday, November 15, 2011 at 9:00 a.m. Eastern Time.  The presentation will be webcast live.

To access the presentation via the Web, please go to the Alexza Investor Relations tab at www.alexza.com or directly http://www.wsw.com/webcast/lz11/alxa/.  A replay of the webcast will be available approximately 24 hours after the presentation and archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
2. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
3. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
4. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
5. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
6. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
7. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
8. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
9. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
10. Alexza to Present at the MDB Bright Lights Conference 2011
11. Alexza Prices $16.1 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, ... study reveals trends, R&D progress, and predicted revenues Where is ... sector you must read this brand new report. Visiongain,s ... trends, opportunities and business prospects there. ... Discover How to Stay Ahead Our 205-page ...
(Date:1/24/2017)... Sherpa Clinical Packaging ( www.sherpaclinical.com ), ... pleased to announce the appointment of Kevin Rosenthal as the ... team to lead Sherpa,s Operations group and take ... Kevin is not new to the ... has extensive experience working for leading pharma and ...
(Date:1/24/2017)... India , January 24, 2017 According ... Regulators Market - Global Opportunity Analysis and Industry Forecast, ... at $4,456 million in 2015, and is expected to reach $7,065 ... to 2022. Asia-Pacific generated the highest revenue ... North America and Europe ...
Breaking Medicine Technology:
(Date:1/24/2017)... , ... January 24, 2017 , ... A fifth-year speaker ... of Cypress Benefit Administrators, will return to present about the state of the Affordable ... a “Benefits Adventure” theme this year – will be hosted at Disney’s Grand Californian ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... the expansion of its Medication Counseling Centers to address market needs. To support ... MCC staff by more than 60 percent over the past 6 months. The ...
(Date:1/24/2017)... New York, New York (PRWEB) , ... January 24, 2017 , ... ... demand for Brazilian butt lifts is on the rise. According to the American ... buttock augmentations since 2000. On average, these procedures are performed every 30 minutes of ...
(Date:1/24/2017)... Bethesda, MD (PRWEB) , ... January 24, 2017 ... ... Medical Informatics Association (AMIA) commended the Patient-Centered Outcomes Research Institute (PCORI) for developing ... informaticians suggested that PCORI consider requiring a preliminary data sharing plan as part ...
(Date:1/24/2017)... ... January 24, 2017 , ... To answer the growing demand ... Companies, has designated The Deco a 55 and over residence. ... older in no less than 80% of occupied units. The Deco’s 114 apartments are ...
Breaking Medicine News(10 mins):